Brief: Intercept Resubmits New Drug Application FDA For Obeticholic Acid In Patients With Liver Fibrosis Due To Nash
23/12/2022 12:54
Dec 23 (Reuters) - Intercept Pharmaceuticals Inc
ICPT.O :
* INTERCEPT RESUBMITS NEW DRUG APPLICATION TO U.S. FDA FOR
OBETICHOLIC ACID IN PATIENTS WITH LIVER FIBROSIS DUE TO NASH
* INTERCEPT PHARMACEUTICALS INC - ANTICIPATES FDA WILL
CLASSIFY
THIS APPLICATION AS A CLASS 2 RESUBMISSION WITH A PDUFA TARGET
REVIEW TIME OF 6 MONTHS
Source text for Eikon: ID:nGNXpsS1l
Further company coverage: ICPT.O
((Reuters.Briefs@thomsonreuters.com))
Recent news on Intercept Pharmaceuticals
See all newsIntercept Pharmaceuticals Inc expected to post a loss of 44 cents a share - Earnings Preview
U.S. RESEARCH ROUNDUP-Digitalbridge Group, Huntington Ingalls Industries, Workday
U.S. RESEARCH ROUNDUP-Docusign, Immunovant, Liberty Energy
U.S. STOCKS ON THE MOVE-Amazon, United Parcel Service, Nike
U.S. STOCKS ON THE MOVE-BullFrog AI, Soleno,